title: Post-transplant malignant neoplasia associated with cyclosporine-based immunotherapy: prevalence, risk factors and survival in feline renal transplant recipients.
abstract: The study objective was to compare the prevalence of malignant neoplasia in feline renal transplant recipients (n = 111) with a control population of cats that did not receive transplantation (n = 142); and to determine whether the development of post-transplant malignant neoplasia (PTMN) affects long-term survival. Twenty-five (22.5%) renal transplant recipients were diagnosed with PTMN, and of those 14 (56%) were diagnosed with lymphoma. The overall survival time in cats that developed PTMN following renal transplantation (median 646 days, IQR 433-1620 days) was not significantly different from the survival time in cats that did not develop PTMN (median 728 days, IQR 201-1942 days), although median survival after diagnosis of PTMN was only 13 days. Six control cats (4.2%) were diagnosed with malignant neoplasia. Compared to the control population, transplant cats had a 6.6 times higher odds of developing malignant neoplasia and a 6.7 times higher odds of developing lymphoma.
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: C
authors.initials: C
authors.lastname: Wormser
authors.affiliation: Department of Clinical Sciences, Tufts University, North Grafton, Massachusetts, USA.
authors.forename: A
authors.initials: A
authors.lastname: Mariano
authors.affiliation: Veterinary Specialty Hospital of the Carolinas, Cary, North Carolina, USA.
authors.forename: E S
authors.initials: ES
authors.lastname: Holmes
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: L R
authors.initials: LR
authors.lastname: Aronson
authors.affiliation: Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
authors.forename: S W
authors.initials: SW
authors.lastname: Volk
mesh_terms: D000818:Animals; D016022:Case-Control Studies; D002371:Cat Diseases / Q000139:chemically induced* / Q000473:pathology; D002415:Cats; D016572:Cyclosporine / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects / Q000662:veterinary*; D008297:Male; D009369:Neoplasms / Q000209:etiology / Q000473:pathology / Q000662:veterinary*; D016017:Odds Ratio; D012189:Retrospective Studies; D012307:Risk Factors; D016019:Survival Analysis
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine
keywords: Comparative oncology; Oncology; Pathology; Small animal; Tumour biology